By Application
Hot products 
-
Mouse Anti-ALOX5 Recombinant Antibody (33) (CBMAB-1890CQ)
-
Mouse Anti-GLP1R Recombinant Antibody (4F3) (CBMAB-G0521-LY)
-
Mouse Anti-ANXA7 Recombinant Antibody (A-1) (CBMAB-A2941-YC)
-
Mouse Anti-CTCF Recombinant Antibody (CBFYC-2371) (CBMAB-C2443-FY)
-
Mouse Anti-AZGP1 Recombinant Antibody (CBWJZ-007) (CBMAB-Z0012-WJ)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Mouse Anti-ATG5 Recombinant Antibody (9H197) (CBMAB-A3945-YC)
-
Mouse Anti-CD59 Recombinant Antibody (CBXC-2097) (CBMAB-C4421-CQ)
-
Mouse Anti-CD247 Recombinant Antibody (6B10.2) (CBMAB-C1583-YY)
-
Mouse Anti-CA9 Recombinant Antibody (CBXC-2079) (CBMAB-C0131-CQ)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-CCDC6 Recombinant Antibody (CBXC-0106) (CBMAB-C5397-CQ)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Mouse Anti-C5B-9 Recombinant Antibody (CBFYA-0216) (CBMAB-X0304-FY)
-
Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)
-
Mouse Anti-AGO2 Recombinant Antibody (V2-634169) (CBMAB-AP203LY)
-
Mouse Anti-EMP3 Recombinant Antibody (CBFYE-0100) (CBMAB-E0207-FY)
-
Mouse Anti-BIRC3 Recombinant Antibody (16E63) (CBMAB-C3367-LY)
-
Mouse Anti-AAV-5 Recombinant Antibody (V2-503416) (CBMAB-V208-1402-FY)
-
Mouse Anti-BACE1 Recombinant Antibody (CBLNB-121) (CBMAB-1180-CN)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
